Somatic alterations as the basis for resistance to targeted therapies

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 244-254

  Blair, Brian G ^a   Bardelli, Alberto ^b   Park, Ben Ho ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

cancer; drug resistance; somatic alterations; targeted therapies

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; CRIZOTINIB; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; K RAS PROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAPAMYCIN; RIDAFOROLIMUS; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR; VEMURAFENIB;

AMINO ACID SUBSTITUTION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COMPETITIVE INHIBITION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INHIBITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LIVER CANCER; LYMPHOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; ONCOGENE C KIT; PANCREAS CANCER; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SINGLE STRANDED DNA BREAK; SOMATIC MUTATION; UPREGULATION;

CANCER; DRUG RESISTANCE; SOMATIC ALTERATIONS; TARGETED THERAPIES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84890285771     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4278     Document Type: Review

References (148)

1. Capdeville R, Buchdunger E, Zimmermann J, et al., Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1 (7): 493-502.
2. Nowell P, Hungerford D,. Minute chromosome in human chronic granulocytic leukemia. Science 1960; 1497.
3. Rowley JD,. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243 (5405): 290-293.
4. Waller CF,. Imatinib mesylate. Recent Results Cancer Res 2010; 184: 3-20.
5. Schindler T., Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289 (5486): 1938-1942.
6. Lopes LF, Bacchi CE,. Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med 2010; 14 (1-2): 42-50.
7. Bixby D, Talpaz M,. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011; 25 (1): 7-22.
8. Engelman JA, Settleman J,. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008; 18 (1): 73-79.
9. Gorre ME, Mohammed M, Ellwood K, et al., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, NY) 2001; 293 (5531): 876-880.
10. Griswold IJ, MacPartlin M, Bumm T, et al., Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26 (16): 6082-6093.
11. Faivre S, Demetri G, Sargent W, et al., Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6 (9): 734-745.
12. Wilhelm S, Carter C, Lynch M, et al., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5 (10): 835-844.
13. Wan PTC, Garnett MJ, Roe SM, et al., Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116 (6): 855-867.
14. Keating GM, Santoro A,. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69 (2): 223-240.
15. Abrams TJ, Murray LJ, Pesenti E, et al., Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer. Mol Cancer Therap 2003; 2 (10): 1011-1021.
16. Barattè S, Sarati S, Frigerio E, et al., Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A 2004; 1024 (1-2): 87-94.
17. Le Tourneau C, Raymond E, Faivre S,. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Therap Clin Risk Manage 2007; 3 (2): 341-348.
18. Mendel DB, Laird AD, Xin X, et al., In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9 (1): 327-337.
19. O'Farrell AM, Foran JM, Fiedler W, et al., An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9 (15): 5465-5476.
20. Demetri GD, van Oosterom AT, Garrett CR, et al., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368 (9544): 1329-1338.
21. Bergers G, Hanahan D,. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8 (8): 592-603.
22. Gotink KJ, Broxterman HJ, Labots M, et al., Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 2011; 17 (23): 7337-7346.
23. Shojaei F, Lee JH, Simmons BH, et al., HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010; 70 (24): 10090-10100.
24. Heitman J, Movva NR, Hall MN,. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science (New York, NY) 1991; 253 (5022): 905-909.
25. Foster KG, Fingar DC,. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 2010; 285 (19): 14071-14077.
26. 1-arresting rapamycin-receptor complex. Nature 1994; 369 (6483): 756-758.
27. Huang S, Bjornsti M-A, Houghton PJ,. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther. 2003; 2 (3): 222-232.
28. Dobashi Y, Watanabe Y, Miwa C, et al., Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011; 4 (5): 476-495.
29. Bjornsti M-A, Houghton PJ,. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4 (5): 335-348.
30. Faivre S, Kroemer G, Raymond E,. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5 (8): 671-688.
31. Yuan R, Kay A, Berg WJ, et al., Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009; 2 (1): 45.
32. Dumont FJ, Staruch MJ, Grammer T, et al., Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. Cell Immunol 1995; 163 (1): 70-79.
33. Fruman DA, Wood MA, Gjertson CK, et al., FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol 1995; 25 (2): 563-571.
34. Lorenz MC, Heitman J,. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 1995; 270 (46): 27531-27537.
35. Carracedo A, Ma L, Teruya-Feldstein J, et al., Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118 (9): 3065-3074.
36. Shi Y, Yan H, Frost P, et al., Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/ phosphatidylinositol 3-kinase cascade. Mol Cancer Therap 2005; 4 (10): 1533-1540.
37. Tan J, Lee PL, Li Z, et al., B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell 2010; 18 (5): 459-471.
38. Sarbassov DD, Guertin DA, Ali SM, et al., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (New York, NY) 2005; 307 (5712): 1098-1101.
39. Dilling MB, Germain GS, Dudkin L, et al., 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002; 277 (16): 13907-13917.
40. Graff JR, Konicek BW, Carter JH, et al., Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008; 68 (3): 631-634.
41. Mahalingam D, Medina EC, Esquivel JA, et al., Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 2010; 16 (1): 141-153.
42. Majumder PK, Febbo PG, Bikoff R, et al., mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10 (6): 594-601.
43. Guba M, von Breitenbuch P, Steinbauer M, et al., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8 (2): 128-135.
44. Chapuis N, Tamburini J, Green AS, et al., Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 2010; 24 (10): 1686-1699.
45. + leukemia cells. J Clin Invest 2008; 118 (9): 3038-3050.
46. Ishibashi K, Suzuki M, Sasaki S, et al., Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and β subunit of the high-affinity IgE receptor. Gene 2001; 264 (1): 87-93.
47. Nadler LM, Ritz J, Hardy R, et al., A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981; 67 (1): 134-140.
48. Tedder TF, Engel P,. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15 (9): 450-454.
49. Oettgen HC, Bayard PJ, Van Ewijk W, et al., Further biochemical studies of the human B-cell differentiation antigens B1 and B2. Hybridoma 1983; 2 (1): 17-28.
50. Grillo-Lõpez AJ, White CA, Varns C, et al., Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26 (5, suppl 14): 66-73.
51. Rudnicka D, Oszmiana A, Finch DK, et al., Rituximab causes a polarisation of B cells which augments its therapeutic function in NK cell-mediated antibody-dependent cellular cytotoxicity. Blood 2013; 121: 4694-4702.
52. Glennie MJ, French RR, Cragg MS, et al., Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44 (16): 3823-3837.
53. Cartron G, Dacheux L, Salles G, et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99 (3): 754-758.
54. Clynes RA, Towers TL, Presta LG, et al., Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6 (4): 443-446.
55. Rezvani AR, Maloney DG,. Rituximab resistance. Best practice and research. Clin Haematol 2011; 24 (2): 203-216.
56. Weiner GJ,. Rituximab: mechanism of action. Semin Hematol 2010; 47 (2): 115-123.
57. Jazirehi AR, Vega MI, Bonavida B,. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007; 67 (3): 1270-1281.
58. Euhus DM, Robinson L,. Genetic predisposition syndromes and their management. Surg Clin N Am 2013; 93 (2): 341-362.
59. Patel K., Involvement of Brca2 in DNA repair. Mol Cell 1998; 1 (3): 347-357.
60. Moynahan ME, Pierce AJ, Jasin M,. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7 (2): 263-272.
61. Moynahan ME, Chiu JW, Koller BH, et al., Brca1 controls homology-directed DNA repair. Mol Cell 1999; 4 (4): 511-518.
62. Lomonosov M, Anand S, Sangrithi M, et al., Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev 2003; 17 (24): 3017-3022.
63. Gradwohl G, Ménissier de Murcia JM, Molinete M, et al., The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA. Proc Natl Acad Sci USA 1990; 87 (8): 2990-2994.
64. McGlynn P, Lloyd RG,. Recombinational repair and restart of damaged replication forks. Nat Rev Mol Cell Biol 2002; 3 (11): 859-870.
65. Rouleau M, Patel A, Hendzel MJ, et al., PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10 (4): 293-301.
66. Saleh-Gohari N, Bryant HE, Schultz N, et al., Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 2005; 25 (16): 7158-7169.
67. Thompson LH,. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res 751 (2): 158-246.
68. Helleday T, Petermann E, Lundin C, et al., DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8 (3): 193-204.
69. Murai J, Huang SN, Das BB, et al., Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72 (21): 5588-5599.
70. Ashworth A., Drug resistance caused by reversion mutation. Cancer Res 2008; 68 (24): 10021-10023.
71. Edwards SL, Brough R, Lord CJ, et al., Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451 (7182): 1111-1115.
72. Domagala P, Huzarski T, Lubinski J, et al., PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 2011; 127 (3): 861-869.
73. Bouwman P, Aly A, Escandell JM, et al., 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010; 17 (6): 688-695.
74. Bunting SF, Callén E, Wong N, et al., 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141 (2): 243-254.
75. Sjögren S, Inganäs M, Lindgren A, et al., Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16 (2): 462-469.
76. Slamon DJ, Godolphin W, Jones LA, et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, NY) 1989; 244 (4905): 707-712.
77. Cuello M, Ettenberg SA, Clark AS, et al., Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001; 61 (12): 4892-4900.
78. Molina MA, Codony-Servat J, Albanell J, et al., Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61 (12): 4744-4749.
79. Bange J, Zwick E, Ullrich A,. Molecular targets for breast cancer therapy and prevention. Nat Med 2001; 7 (5): 548-552.
80. Junttila TT, Akita RW, Parsons K, et al., Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15 (5): 429-440.
81. Lim B, Cream L V, Harvey HA,. Update on clinical trials: genetic targets in breast cancer. Adv Exp Med Biol 2013; 779: 35-54.
82. Stopeck AT, Brown-Glaberman U, Wong HY, et al., The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metast 2012; 29 (7): 807-819.
83. Bachman KE, Argani P, Samuels Y, et al., The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Therap 2004; 3 (8): 772-775.
84. Park BH, Davidson NE,. PI3 kinase activation and response to trastuzumab therapy: what's neu with herceptin resistance? Cancer Cell 2007; 12 (4): 297-299.
85. Gustin JP, Cosgrove DP, Park BH,. The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets 2008; 8 (8): 733-740.
86. Nagata Y, Lan KH, Zhou X, et al., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6 (2): 117-127.
87. Berns K, Horlings HM, Hennessy BT, et al., A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12 (4): 395-402.
88. Hynes NE, Lane HA,. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5 (5): 341-354.
89. Lee-Hoeflich ST, Crocker L, Yao E, et al., A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68 (14): 5878-5887.
90. Sergina N V, Rausch M, Wang D, et al., Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445 (7126): 437-441.
91. Ritter CA, Perez-Torres M, Rinehart C, et al., Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13 (16): 4909-4919.
92. Lu Y, Zi X, Zhao Y, et al., Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93 (24): 1852-1857.
93. Nahta R, Yuan LXH, Zhang B, et al., Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65 (23): 11118-11128.
94. Sáez R, Molina MA, Ramsey EE, et al., p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006; 12 (2): 424-431.
95. Franklin MC, Carey KD, Vajdos FF, et al., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5 (4): 317-328.
96. Adams CW, Allison DE, Flagella K, et al., Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006; 55 (6): 717-727.
97. Engelman JA, Zejnullahu K, Mitsudomi T, et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (New York, NY) 2007; 316 (5827): 1039-1043.
98. Recupero D, Daniele L, Marchiò C, et al., Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. J Pathol 2013; 229 (3): 390-399.
99. Scheuer W, Friess T, Burtscher H, et al., Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69 (24): 9330-9336.
100. Lewis Phillips GD, Li G, Dugger DL, et al., Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68 (22): 9280-9290.
101. Junttila TT, Li G, Parsons K, et al., Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011; 128 (2): 347-356.
102. Hurvitz SA, Hu Y, O'Brien N, et al., Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2013; 39 (3): 219-229.
103. Bose R, Kavuri SM, Searleman AC, et al., Activating HER2 mutations in HER2 gene amplification-negative breast cancer. Cancer Discov 2013; 3 (2): 224-237.
104. Liu L, Greger J, Shi H, et al., Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009; 69 (17): 6871-6878.
105. Xia W, Bacus S, Hegde P, et al., A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006; 103 (20): 7795-7800.
106. Barker AJ, Gibson KH, Grundy W, et al., Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11 (14): 1911-1914.
107. Wakeling AE, Guy SP, Woodburn JR, et al., ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62 (20): 5749-5754.
108. Sharma S V, Bell DW, Settleman J, et al., Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7 (3): 169-181.
109. Kosaka T, Yatabe Y, Endoh H, et al., Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64 (24): 8919-8923.
110. Kobayashi S, Boggon TJ, Dayaram T, et al., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352 (8): 786-792.
111. Pao W, Miller VA, Politi KA, et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2 (3): e73.
112. Yun C-H, Mengwasser KE, Toms A V, et al., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105 (6): 2070-2075.
113. Kwak EL, Sordella R, Bell DW, et al., Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102 (21): 7665-7670.
114. Balak MN, Gong Y, Riely GJ, et al., Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12 (21): 6494-6501.
115. Tokumo M, Toyooka S, Ichihara S, et al., Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 2006; 53 (1): 117-121.
116. Xu Y, Liu H, Chen J, et al., Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol Therap Landes Biosci 2010; 9 (8): 572-582.
117. Li S, Schmitz KR, Jeffrey PD, et al., Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7 (4): 301-311.
118. Brand TM, Iida M, Wheeler DL,. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Therap 2011; 11 (9): 777-792.
119. Di Fiore F, Blanchard F, Charbonnier F, et al., Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96 (8): 1166-1169.
120. De Roock W, Piessevaux H, De Schutter J, et al., KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19 (3): 508-515.
121. Amado RG, Wolf M, Peeters M, et al., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26 (10): 1626-1634.
122. Diaz LA, Williams RT, Wu J, et al., The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486 (7404): 537-540.
123. Misale S, Yaeger R, Hobor S, et al., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486 (7404): 532-536.
124. Di Nicolantonio F, Martini M, Molinari F, et al., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26 (35): 5705-5712.
125. Sartore-Bianchi A, Martini M, Molinari F, et al., PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69 (5): 1851-1857.
126. Bardelli A, Corso S, Bertotti A, et al., Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013; 3 (6): 658-673.
127. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417 (6892): 949-954.
128. Tsai J, Lee JT, Wang W, et al., Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105 (8): 3041-3046.
129. Hatzivassiliou G, Song K, Yen I, et al., RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464 (7287): 431-435.
130. Flaherty KT, Puzanov I, Kim KB, et al., Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363 (9): 809-819.
131. Flaherty KT, Infante JR, Daud A, et al., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367 (18): 1694-1703.
132. Nazarian R, Shi H, Wang Q, et al., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468 (7326): 973-977.
133. Trunzer K, Pavlick AC, Schuchter L, et al., Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013; 31 (14): 1767-1774.
134. Straussman R, Morikawa T, Shee K, et al., Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487 (7408): 500-504.
135. Prahallad A, Sun C, Huang S, et al., Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483 (7387): 100-103.
136. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448 (7153): 561-566.
137. Sasaki T, Rodig SJ, Chirieac LR, et al., The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46 (10): 1773-1780.
138. Peters S, Taron M, Bubendorf L, et al., Treatment and detection of ALK-rearranged NSCLC. Lung Cancer 2013; 81: 145-154.
139. Christensen JG, Zou HY, Arango ME, et al., Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Therap 2007; 6 (12, pt 1): 3314-3322.
140. Zou HY, Li Q, Lee JH, et al., An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67 (9): 4408-4417.
141. Choi YL, Soda M, Yamashita Y, et al., EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363 (18): 1734-1739.
142. Katayama R, Shaw AT, Khan TM, et al., Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Translat Med 2012; 4 (120): 120ra17.
143. Tanizaki J, Okamoto I, Okabe T, et al., Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 2012; 18 (22): 6219-6226.
144. Samuels Y, Wang Z, Bardelli A, et al., High frequency of mutations of the PIK3CA gene in human cancers. Science (New York, NY) 2004; 304 (5670): 554.
145. Janku F, Wheler JJ, Naing A, et al., PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013; 73 (1): 276-284.
146. Janku F, Wheler JJ, Westin SN, et al., PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30 (8): 777-782.
147. Marone R, Cmiljanovic V, Giese B, et al., Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784 (1): 159-185.
148. Carpten JD, Faber AL, Horn C, et al., A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448 (7152): 439-444.